LLY Raises Full-Year Outlook After Zepbound and Mounjaro Drive Beat
What happened
Eli Lilly reported quarterly results that exceeded analyst estimates and lifted its full-year financial outlook, citing surging demand for its GLP-1 weight-loss drug Zepbound and diabetes treatment Mounjaro as the primary growth drivers. Sales of both drugs came in above expectations. Management increased forward guidance, signaling continued confidence in the commercial trajectory of its obesity and diabetes franchise.
The QL Read
LLY's composite signal sits at 63/100 and the stock is up 6.37% on the session, a positive reception against a near-flat-breadth tape (50.4% advancing). The guidance raise is directionally consistent with the current signal, though the 63 reading leaves the score mid-range pending confirmation from subsequent GLP-1 volume data.